ASCO 2022 Conference Coverage

 

GU
21:32

ASCO 2022 Conference Coverage

ASCO 2022 Bladder Cancer Highlights

FEATURING Guru Sonpavde
  • 810 views
  • July 12, 2022
04:42

ASCO 2022 Conference Coverage

ASCO 2022 on Olaparib + Abiraterone as 1L Therapy for mCRPC: Pharmacokinetics Data From the PROpel Trial

FEATURING Andrew Armstrong
  • 264 views
  • July 9, 2022
06:04

ASCO 2022 Conference Coverage

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 Bispecific Checkpoint Inhibitor, as Monotherapy With Advanced RCC: Preliminary Results From the FTIH Trial

FEATURING Laurence Albiges
  • 139 views
  • June 30, 2022
05:15

ASCO 2022 Conference Coverage

ASCO 2022 on the Clinical Outcomes & Safety of Enzalutamide + ADT in mHSPC in Patients Aged <75 and ≥ 75 years: ARCHES Post Hoc Analysis

FEATURING Russell Szmulewitz
  • 176 views
  • June 23, 2022
04:00

ASCO 2022 Conference Coverage

ASCO 2022 CHAARTED Trial: Eight-Year Survival Rates by Baseline Prognostic Groups in Pts With mHSPC: An Analysis From ECOG-ACRIN 3805

FEATURING Abhishek Tripathi
  • 265 views
  • June 17, 2022
03:11

ASCO 2022 Conference Coverage

ASCO 2022 Defining "Platinum-Ineligible" Pts With Metastatic Urothelial Cancer

FEATURING Shilpa Gupta
  • 259 views
  • June 14, 2022
  • 1
03:44

ASCO 2022 Conference Coverage

ASCO 2022 MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs. Avelumab After 1L Platinum-Based Chemo in Pts With mUC (Alliance A032001)

FEATURING Shilpa Gupta
  • 722 views
  • June 14, 2022
  • 1
20:21

ASCO 2022 Conference Coverage

ASCO 2022 Highlights From Educational Sessions and Updates in Bladder Cancer

FEATURING Petros Grivas
  • 728 views
  • June 13, 2022
  • 4
30:41

ASCO 2022 Conference Coverage

ASCO 2022 Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to Lu-PSMA-617 in mCRPC: A VISION Substudy

FEATURING Phillip Kuo
  • 307 views
  • June 10, 2022
  • 1
01:22

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Real-World Treatment Patterns and Clinical Outcomes With 1L Therapy in Cisplatin-(In)eligible Patients With Advanced Urothelial Carcinoma

FEATURING Guru Sonpavde
  • 12 views
  • June 9, 2022
09:17

ASCO 2022 Conference Coverage

ASCO 2022 Real-World Treatment Patterns and Clinical Outcomes With 1L Therapy in Cisplatin-(In)eligible Patients With Advanced Urothelial Carcinoma

FEATURING Guru Sonpavde
  • 185 views
  • June 9, 2022
  • 1
09:23

ASCO 2022 Conference Coverage

ASCO 2022 on Randomized Phase II Trial of Neoadjuvant ADT + Abiraterone & Apalutamide for High-Risk Localized Prostate Cancer: Pathologic Response and PSMA Imaging Correlates

FEATURING Diogo Bastos
  • 254 views
  • June 9, 2022
08:05

ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder Preservation for Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations (Alliance A031701)

FEATURING Gopa Iyer
  • 131 views
  • June 8, 2022
05:47

ASCO 2022 Conference Coverage

ASCO 2022 Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up in R/R RCC

FEATURING Brian Rini
  • 644 views
  • June 8, 2022
  • 3